Sign in

    Gavin Kluck

    Managing Director and Senior Equity Research Analyst at Evercore ISI

    Gavin Kluck is a Managing Director and Senior Equity Research Analyst at Evercore ISI, specializing in the coverage of regional banks and specialty finance companies. He covers prominent institutions such as Regions Financial, Fifth Third Bancorp, Huntington Bancshares, and Comerica, and has built a reputation for generating actionable investment insights, reflected in his TipRanks profile with a success rate above 60% and strong average returns per recommendation. Kluck began his career in equity research at Morgan Stanley, later joining Keefe, Bruyette & Woods, and then moving to Evercore ISI in 2021 where he has quickly established himself as a trusted voice in bank equity research. His credentials include FINRA registration with Series 7, 63, 86, and 87 licenses, underscoring his professional expertise and regulatory standing in the securities industry.

    Gavin Kluck's questions to Crinetics Pharmaceuticals (CRNX) leadership

    Gavin Kluck's questions to Crinetics Pharmaceuticals (CRNX) leadership • Q2 2025

    Question

    An analyst on behalf of Gavin Kluck from Evercore ISI asked if the early 2026 data readout for Cohort 4 of the adult Phase II CAH study would also include an update on data from the open-label extension (OLE).

    Answer

    Founder and CEO R. Scott Struthers confirmed that the company plans to provide a broader update on the entire adamelin program at that time. This will include not only Cohort 4 and OLE data but also updates on the ramp-up of the adult and pediatric CAH studies and clarity on the Cushing's disease program.

    Ask Fintool Equity Research AI